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members have presented research at international meet-
ings on the initiation of prophylaxis in children, use of 
immune tolerance induction in adults, and prevalence of 
acute coronary syndromes in older patients with hemo-
philia. The main goal of the continuing work of GEHEP is 
to advance the care of patients with hemophilia world-
wide.
Introduction
Hemophilia A and B are inherited bleeding disorders re-
sulting from a deficiency of clotting factor VIII and factor IX, 
respectively [1]. As X-linked disorders, both types of hemo-
philia occur almost exclusively in boys, with an incidence of 1 
in 5,000 male births for hemophilia A and 1 in 25,000 male 
births for hemophilia B [1]. Hemophilia severity is defined by 
the level of clotting factor present in blood (severe <1% of 
normal levels; moderate 1–5%; mild >5 to <40%) [2]. Patients 
with mild hemophilia typically experience excessive bleeding 
only after serious injury, trauma, or surgery; those with mod-
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Summary
GEHEP, established in 2009, is an independent, multi-in-
stitutional, international consortium of early career he-
matology specialists in the field of hemophilia and other 
inherited bleeding disorders. The main objective of the 
group, whose members practice at institutions in North 
America, Europe, and South Africa, is to advance hemo-
philia care by providing a forum for mentored collabora-
tive research, developing programs for improving clini-
cal care, and promoting academic career development of 
junior faculty. GEHEP members collect and document 
anonymized data on intra- and interinstitutional differ-
ences in patient populations, diagnosis, and treatment in 
the field of hemophilia and other bleeding disorders. To 
facilitate sharing of aggregated data among GEHEP 
members, a global protocol was developed and ap-
proved by most members’ local institutional review 
board. Current GEHEP research initiatives are varied, en-
compassing work in pediatric and adult patients. GEHEP 
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treatment centers, primarily academic institutions, in Can-
ada, Germany, Italy, Norway, South Africa, Spain, the UK, 
and the USA. 
Because diagnostic methods, treatment approaches, and 
management of age-related comorbidities vary among study 
centers, a principal aim of GEHEP is to document and study 
intra- and interinstitutional differences in patient populations, 
diagnosis, and treatment to provide a basis for identifying fu-
ture areas of research. All GEHEP projects are reviewed and 
approved by the local institutional review board (IRB) of 
each member. Information included in the GEHEP project 
databases is collected through written or electronic surveys 
approved and completed by all GEHEP members. Many of 
the participating treatment centers maintain local databases 
of clinical data, which are accessed to provide information 
about the patient population of interest. In cases in which spe-
cific information is required, patient medical records are re-
viewed, and only anonymized patient data are included in the 
database. For example, patient name, address, birth date, ad-
mission and discharge dates, social security number, medical 
record number, full-face photograph, or any other unique 
identifying data are not collected.
Data collected in the GEHEP databases, which are project-
specific and maintained at the project leader’s institution, in-
clude demographic data, number of patients at each center 
with hemophilia A or hemophilia B, and disease severity. In 
addition, more specific data are collected as required by the 
many ongoing or completed GEHEP-independent research 
projects. Examples of such data include treatment provided in 
various settings (e.g., management of acute coronary syn-
dromes or patients undergoing orthopedic surgery), results 
and complications of treatment, and comorbidities. Data col-
lection has also included the types of laboratory tests availa-
ble at each center for evaluation of patients experiencing 
bleeding episodes and the general practices or guidelines fol-
lowed in specific clinical situations. The databases are acces-
sible only by GEHEP members, and all data analyses are per-
formed by GEHEP.
Research Initiatives
Members of GEHEP meet annually to discuss current and 
future research initiatives. Additional meetings are held in con-
junction with major international hematology congresses, such 
as those of the American Society of Hematology, the Interna-
tional Society on Thrombosis and Haemostasis (ISTH), and the 
World Federation of Hemophilia (WFH). Invited lectures at 
some of these meetings by experts in the field of study design 
and public health further assist in the critical thinking process.
These initiatives encompass a range of research interests, 
all of which are designed to bring an international perspective 
to advancing patient care. To facilitate this, a key overall goal 
of GEHEP was to develop a single global protocol approved 
erate hemophilia bleed excessively after injury but also some-
times spontaneously. In patients with severe hemophilia, 
spontaneous bleeding episodes are common, particularly into 
muscles and joints [3]. No ethnic or geographic predisposition 
to hemophilia has been identified [1], but geographic differ-
ences are seen in diagnosis, treatment approaches, and access 
to treatment. Particularly in developing countries, hemophilia 
is underdiagnosed and undertreated [4].
Bleeding episodes in patients with hemophilia are treated 
or prevented by infusion of the deficient clotting factor, using 
either plasma-derived or recombinant factor replacement 
products. Optimal care of patients with hemophilia requires a 
comprehensive approach delivered by a multidisciplinary 
team of specialists [5]. This specialized care, which encom-
passes the medical and psychological aspects of hemophilia, is 
generally delivered in a dedicated hemophilia treatment 
center [5]. Typically, these specialized clinics also provide care 
for patients with other inherited bleeding disorders, including 
von Willebrand disease, other coagulation factor deficiencies, 
and platelet disorders.
Despite advances in the management of hemophilia and 
other bleeding disorders, access to specialized centers and 
comprehensive care, coupled with a shortage of physicians 
trained in the management of hemostasis and thrombosis, re-
mains a challenge. Attrition of specialized healthcare provid-
ers and senior clinicians threatens the existence of some he-
mophilia treatment centers [6]. The Global Emerging HEmo-
philia Panel (GEHEP) was established in 2009 to address 
some of the workforce challenges and to create a consortium 
of junior faculty to foster collaborative research that benefits 
patients and is a vital component for the success of academic 
faculty. Thus, in addition to improving clinical practice inter-
nationally, GEHEP enhances career development by provid-
ing research opportunities and encouraging collaboration 
among contemporaries. Mentorship for GEHEP members is 
currently provided by 2 senior researchers in the field of he-
mophilia and inherited bleeding disorders: Dr. Gerry Dolan 
(Nottingham University Hospitals, Nottingham, UK) and Dr. 
Roshni Kulkarni (Michigan State University, East Lansing, 
MI, USA). Before joining the National Heart, Lung, and 
Blood Institute (Bethesda, MD, USA), Dr. Donna DiMichele 
had served as a GEHEP mentor. Administrative and meeting 
support for GEHEP is provided by Bayer HealthCare.
Global Emerging HEmophilia Panel
GEHEP is an independent, multi-institutional, interna-
tional consortium of physicians who manage both pediatric 
and adult patients with hemophilia or other inherited bleed-
ing disorders. The objective of the group is to advance pa-
tient care by providing a forum for multinational collabora-
tive research by emerging leaders in the field of hemostasis, 
facilitated by mentors. Current GEHEP members practice at 
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by each GEHEP member’s IRB to promote sharing of ano-
nymized aggregated data. Almost all participating centers had 
the global protocol approved by their respective institutions 
within the first 2 years of the group’s inception.
Global Protocol
The objective of the global protocol is to provide an um-
brella protocol under which a number of research projects can 
be initiated, thereby streamlining the IRB process. The spe-
cific goal is to collect and document intra- and interinstitu-
tional anonymized data from each GEHEP center on the di-
agnosis and management of hemophilia and hemophilic com-
plications in children and adults and of diseases of aging in the 
hemophilic population.
Because of interinstitutional differences in IRB require-
ments, the global protocol was submitted and approved by 
most, but not all, GEHEP centers. At centers that have not 
approved the global protocol, specific project protocols are 
submitted and approved on an individual basis.
Current Research
Research by GEHEP members that has been presented at 
hematology congresses is summarized in table 1. Research ef-
forts currently in progress in pediatric patients include a study 
of the initiation of prophylaxis in children with hemophilia A 
or hemophilia B. This study focuses on criteria used to start 
prophylaxis, choice of factor replacement product, treatment 
regimen and dosage, inhibitor prevalence, rate of break-
through bleeding, and central venous line use. Results from 
this study, describing the technical aspects of implementing 
prophylaxis in children, were presented at the WFH congress 
held in Paris, France, in July 2012 [7]. 
Research in adults includes a study on acute coronary syn-
dromes that drew from a 10-year retrospective database. Re-
sults from this study were presented at the Scientific and 
Standardization Committee meeting of the ISTH held in Liv-
erpool, UK, in June 2012 [8]. A future study has been pro-
posed to gather data on the incidence and management of 
stroke and atrial fibrillation in patients with hemophilia or 
other bleeding disorders.
Another study in adult patients explored GEHEP mem- 
ber practices regarding management of patients with severe 
hemophilia undergoing orthopedic or other surgery. Results 
from this study were presented at the WFH congress held in 
Buenos Aires, Argentina, in July 2010 [9]. A proposal has 
been made to capture additional retrospective data from this 
patient population, including further data on the use of 
thromboprophylaxis, over a 5-year period.
Members of GEHEP have undertaken a two-part research 
initiative on immune tolerance induction (ITI). The first part 
of this project was a survey on inhibitor eradication practices 
in adults. Survey results were presented at the 2010 WFH con-
gress [10]; a follow-up survey is being conducted to further 
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hemophilia and other inherited bleeding disorders. Develop-
ment of a global protocol, approved by each GEHEP mem-
ber’s IRB, facilitates sharing of anonymized aggregated data. 
Collection and documentation of intra- and interinstitutional 
de-identified data provides a foundation on which to base fu-
ture priorities for clinical care and research. Presentations of 
GEHEP research at national and international meetings con-
tribute to the scientific knowledge base, support the career 
development of young investigators, and help promote and 
sustain an adequate workforce in the field of bleeding disor-
ders. These efforts need to be expanded to include investiga-
tors from developing countries. 
Acknowledgments
Medical writing assistance was provided by Karen L. Zimmermann of 
Complete Healthcare Communications, Inc., and was funded by Bayer 
HealthCare.
Disclosure Statement
GEHEP is supported by funding from Bayer HealthCare. 
try to collect data on rituximab use in pediatric and adult pa-
tients with inhibitors. 
Data also have been gathered by GEHEP to determine the 
types of laboratory assessments used to diagnose hemophilia 
A. This work, which was presented at the WFH congress in 
2010 [11], focuses on differences in GEHEP member practices 
regarding types of assays used and genotyping. 
Future Research 
Through the unique prism of this international collabora-
tion, GEHEP research data have improved our understand-
ing of the challenges of caring for patients with hemophilia 
or other inherited bleeding disorders. Future GEHEP areas 
of interest include female carriers, mild hemophilia, mucocu-
taneous bleeding, and vaccination practices. Innovative, new 
prospective studies will be shaped by retrospective data 
collection.
Conclusions
GEHEP is a successful multinational collaboration of spe-
cialists whose goal is to advance research in and treatment of 
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